Evaluation of the Beneficial Health Effects of an Additive-free Meat Product in Healthy Subjects (HIPOCARNE)

April 26, 2024 updated by: Universidad de Murcia
The purpose of this research is to test the hypothesis that the consumption of meat products without additives, in comparison with their analogues with additives, could be beneficial in terms of modifying health markers. A 5-week clinical trial with two parallel arms will be performed with two parallel arms. Changes in different serum biomarkers of lipid metabolism, glucose, oxidative stress and inflammation will be analysed. Biomarkers related to digestive health, such as short chain fatty acid (SCFA) production and impact on the gut microbiota, will also be evaluated. Finally, factors such as body mass index (BMI), body fat percentage and markers of exposure to additives will be measured.

Study Overview

Detailed Description

One of the most discussed reasons for reducing meat consumption is its additive content. Additives are compounds added to food products to preserve their technological properties, to avoid contamination by microorganisms, regulate acidity, and even act as thickeners, emulsifiers, and stabilisers. However, there is some controversy over the actual health effects of additives in meat products, as their long-term effect has not been studied for many of them. On the other hand, not all additives have the same effect, as for antioxidants such as sodium citrate (E-331) and sodium erythorbate (E-316), as well as acidity regulators such and triphosphates (E-451) no side effects or significant toxicity have been reported on healthy individuals. However, other additives such as carrageenans (E-407) have been associated with intestinal inflammation and inflammatory bowel diseases by several animal studies. Negative effects have also been found for sodium nitrite (E-250), which can lead to the formation of carcinogenic N-nitrosamines.

Due to the rising concern about additives in meat products, it is of particular interest to identify the possible health effects of a processed meat product without additives and allergens. Therefore, the hypothesis of this study is that the production of additive-free meat products may be of interest to the consumers and may have a beneficial effect on their health.

To confirm this hypothesis, two meat products without additives or allergens were produced (cooked ham and cooked turkey breast), and a double-blind, randomised, controlled, unicentric trial with two parallel arms will be conducted.

Prior to the start of the intervention period (baseline time) anthropometric measurements and blood, faeces and urine samples will be taken. 58 participants will take alternately 100g of cooked ham or cooked turkey breast (control or reformulated depending on the group) 6 days a week for 5 weeks, noting the rest of their diet in a collection notebook that they will then give to the researchers. After the intervention (final time), anthropometric measurements and blood, faeces and urine samples will be taken again.

Study Type

Interventional

Enrollment (Actual)

58

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Murcia, Spain, 30100
        • Edificio Pleyades-Vitalys

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Subjects of both sexes (men or women) between 18 and 65 years of age
  • Body mass index between 18.5 and 30 Kg / m^2.

Exclusion Criteria:

  • Diabetes mellitus, chronic kidney disease, liver disease, infectious diseases or any type of cancer.
  • Eating disorders, intestinal or similar problems.
  • Subjects in treatment with medication for hypertension or hyperlipaemia.
  • Subjects in treatment with antibiotics in the last 3 months.
  • Subjects who have ingested pre- or probiotic supplements.
  • Subjects who have ingested omega-3 or omega-6 supplements.
  • Patients undergoing major surgery in the last 3 months prior to the beginning of the study.
  • Subjects who have donated blood in the last month prior to the beginning of the study.
  • Subjects with alcohol abuse, or with excessive alcohol consumption.
  • Vegetarian subjects.
  • Pregnant women.
  • Smokers.
  • Participation in other clinical trials in the last 3 months.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention

Consumption of an additive and allergen-free cooked ham or cooked turkey breast.

Quantity: 100 grams.

Consumption time: 6 days a week during 5 weeks.

Baseline time: Measurement of anthropometric parameters and inflammatory and oxidative markers in blood, faeces and urine.

Consumption of meat products without additives and allergens (6 days a week; 5 weeks).

Final time: Measurement of anthropometric parameters and inflammatory and oxidative markers in blood, faeces and urine.

Placebo Comparator: Control

Consumption of a commercial cooked ham or cooked turkey breast.

Quantity: 100 grams.

Consumption time: 6 days a week during 5 weeks.

Baseline time: Measurement of anthropometric parameters and inflammatory and oxidative markers in blood, faeces and urine.

Consumption of commercial meat products (6 days a week; 5 weeks).

Final time: Measurement of anthropometric parameters and inflammatory and oxidative markers in blood, faeces and urine.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in seric lipid profile
Time Frame: At the beginning of the intervention (baseline) and after 5 weeks of product intake (final time)
Seric measurement of triglycerides, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and total cholesterol.
At the beginning of the intervention (baseline) and after 5 weeks of product intake (final time)
Changes in serum levels of oxidative stress
Time Frame: At the beginning of the intervention (baseline) and after 5 weeks of product intake (final time)
Seric measurement of malondialdehyde (MDA), serum glutathione peroxidase (GPx), catalase (CAT), oxidized LDL, Ferric reducing ability of plasma (FRAP) and ABTS (2,2'-azino-bis(3-methylbenzothiazole-6-sulfonic acid).
At the beginning of the intervention (baseline) and after 5 weeks of product intake (final time)
Changes in serum levels of inflammation markers
Time Frame: At the beginning of the intervention (baseline) and after 5 weeks of product intake (final time)
Seric measurement of C-reactive protein (CRP), Tumor necrosis factor α (TNF-α), Interleukin 1β (IL-1β), Interleukin 6 (IL-6) and Interleukin 10 (IL-10).
At the beginning of the intervention (baseline) and after 5 weeks of product intake (final time)
Changes in microbiota composition
Time Frame: At the beginning of the intervention (baseline) and after 5 weeks of product intake (final time)
Measurement of changes in the abundance of the different bacteria present in the gut.
At the beginning of the intervention (baseline) and after 5 weeks of product intake (final time)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Serum levels of glucose
Time Frame: At the beginning of the intervention (baseline) and after 5 weeks of product intake (final time)
At the beginning of the intervention (baseline) and after 5 weeks of product intake (final time)
Serum levels of Alanine Transaminase (ALT) and Aspartate Aminotransferase (AST)
Time Frame: At the beginning of the intervention (baseline) and after 5 weeks of product intake (final time)
At the beginning of the intervention (baseline) and after 5 weeks of product intake (final time)
Changes in the concentration of nitrates in urine
Time Frame: At the beginning of the intervention (baseline) and after 5 weeks of product intake (final time)
At the beginning of the intervention (baseline) and after 5 weeks of product intake (final time)
Changes in faecal levels of oxidative stress
Time Frame: At the beginning of the intervention (baseline) and after 5 weeks of product intake (final time)
Measurement of FRAP levels in faeces.
At the beginning of the intervention (baseline) and after 5 weeks of product intake (final time)
Changes in urine levels of oxidative stress
Time Frame: At the beginning of the intervention (baseline) and after 5 weeks of product intake (final time)
Measurement of FRAP levels in urine.
At the beginning of the intervention (baseline) and after 5 weeks of product intake (final time)
Changes in the concentration of short chain fatty acids in faeces.
Time Frame: At the beginning of the intervention (baseline) and after 5 weeks of product intake (final time)
Measurement of acetate, propionate, butyrate and total SCFA in faeces.
At the beginning of the intervention (baseline) and after 5 weeks of product intake (final time)
Changes in body mass Index (BMI)
Time Frame: At the beginning of the intervention (baseline) and after 5 weeks of product intake (final time)
At the beginning of the intervention (baseline) and after 5 weeks of product intake (final time)
Changes in hip-to-waist ratio
Time Frame: At the beginning of the intervention (baseline) and after 5 weeks of product intake (final time)
At the beginning of the intervention (baseline) and after 5 weeks of product intake (final time)
Changes in body fat mass percentage
Time Frame: At the beginning of the intervention (baseline) and after 5 weeks of product intake (final time)
At the beginning of the intervention (baseline) and after 5 weeks of product intake (final time)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 15, 2023

Primary Completion (Actual)

June 7, 2023

Study Completion (Actual)

June 7, 2023

Study Registration Dates

First Submitted

April 16, 2024

First Submitted That Met QC Criteria

April 26, 2024

First Posted (Actual)

May 1, 2024

Study Record Updates

Last Update Posted (Actual)

May 1, 2024

Last Update Submitted That Met QC Criteria

April 26, 2024

Last Verified

April 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Hipocarne UMU 550/2023

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Inflammation

Clinical Trials on Meat product without additives and allergens

Subscribe